Cat. No：GM-C17940
Product：Jurkat CD3-BsAb Reporter Cell Line
Cat. No：GM-C17940
Product：Jurkat CD3-BsAb Reporter Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640 +1% FBS +1% P.S
Bispecific antibodies (BsAbs) are an emerging cancer treatment method. Unlike traditional monoclonal antibodies that recognize the same antigen with two Fab arms, bispecific antibodies can simultaneously recognize different antigens on two arms. Among many bispecific antibodies, CD3-BsAb (CD3 redirecting bispecific antibody) stands out as it enables T cells to effectively identify and kill cancer cells.
The use of CD3-BsAb for immunotherapy against cancer has been approved for certain hematologic malignancies and is currently undergoing clinical studies for solid tumors. However, treating solid tumors presents more challenges, such as increased off-target toxicity, sparse T cell infiltration, and compromised T cell quality due to the immune-suppressive tumor microenvironment, all impacting the safety and efficacy of CD3-BsAb therapy.
The Jurkat CD3-BsAb Reporter Cell Line by Genomeditechis a reporter gene cell line constructed using Jurkat as the tool cell. The biological activity of CD3-BsAb can be quantified by the BsAb bridging Antigen to activate TCR, signaling transduction to the nucleus, and subsequent luciferase production. This cell line can be used for research on CD3-BsAb anti-cancer drugs.
Cat. No：GM-C17940
Product：Jurkat CD3-BsAb Reporter Cell Line
Cell Growth Medium：RPMI 1640+10% FBS+1% P.S+3.5 μg/mL Blasticidin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：RPMI 1640 +1% FBS +1% P.S
Bispecific antibodies (BsAbs) are an emerging cancer treatment method. Unlike traditional monoclonal antibodies that recognize the same antigen with two Fab arms, bispecific antibodies can simultaneously recognize different antigens on two arms. Among many bispecific antibodies, CD3-BsAb (CD3 redirecting bispecific antibody) stands out as it enables T cells to effectively identify and kill cancer cells.
The use of CD3-BsAb for immunotherapy against cancer has been approved for certain hematologic malignancies and is currently undergoing clinical studies for solid tumors. However, treating solid tumors presents more challenges, such as increased off-target toxicity, sparse T cell infiltration, and compromised T cell quality due to the immune-suppressive tumor microenvironment, all impacting the safety and efficacy of CD3-BsAb therapy.
The Jurkat CD3-BsAb Reporter Cell Line by Genomeditechis a reporter gene cell line constructed using Jurkat as the tool cell. The biological activity of CD3-BsAb can be quantified by the BsAb bridging Antigen to activate TCR, signaling transduction to the nucleus, and subsequent luciferase production. This cell line can be used for research on CD3-BsAb anti-cancer drugs.
